Want to see SE:PILA full AI Analyst Report?
PILA Stock Chart & Stats
kr2.20
-kr0.50(-13.33%)
At close: 4:00 PM EST
kr2.20
-kr0.50(-13.33%)
Day’s Range― - ―
52-Week Rangekr1.02 - kr2.50
Previous CloseN/A
Volume9.62K
Average Volume (3M)127.02K
Market Cap
kr79.49M
Enterprise Valuekr42.98
Total Cash (Recent Filing)kr3.26M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Feb 25, 2027EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding45,682,120
10 Day Avg. Volume83,998
30 Day Avg. Volume127,019
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)4.82
Price to Sales (P/S)63.25
P/FCF Ratio-7.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Financial DebtThe absence of reported debt reduces near-term interest and refinancing pressure, giving PILA greater financial flexibility than a similarly loss-making company with leverage. This can preserve strategic options while it advances development, although it does not eliminate the need for future funding.
Focused Drug DevelopmentA focused therapeutic strategy can concentrate limited resources, expertise, and development effort on a defined disease area with an identifiable clinical objective. XEN-D0501 also offers a differentiated oral-treatment development path, providing a clear basis for future partnering or commercialization if successful.
Expanded Equity BaseThe larger equity base indicates that PILA has obtained additional capital or otherwise strengthened its balance sheet relative to 2024. That provides some support for continuing operations and development activities, though the benefit is tempered by recurring losses and the possibility of further dilution.
Bears Say
Sharp Revenue ContractionA steep decline from an already low revenue base signals that PILA has not established consistent commercial or other recurring revenue. Without improving revenue, the company remains dependent on financing or future development success to support operations and fund its pipeline.
Persistent Operating LossesDeep losses and negative margins show that current activities are not economically self-supporting and that costs materially exceed reported revenue. Continued losses can consume equity, limit investment capacity, and increase the amount of external capital required before any product reaches commercial profitability.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is not generating the cash needed to fund its activities internally. The worsening TTM burn versus 2025 reinforces reliance on external funding, creating continuing financing and potential dilution pressure over the next several quarters.
PILA FAQ
What was PILA PHARMA AB’s price range in the past 12 months?
PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr2.50 in the past 12 months.
What is PILA PHARMA AB’s market cap?
PILA PHARMA AB’s market cap is kr79.49M.
When is PILA PHARMA AB’s upcoming earnings report date?
PILA PHARMA AB’s upcoming earnings report date is Feb 25, 2027 which is in 144 days.
How were PILA PHARMA AB’s earnings last quarter?
PILA PHARMA AB released its earnings results on Aug 27, 2026. The company reported -kr0.08 earnings per share for the quarter, beating the consensus estimate of -kr0.22 by kr0.14.
Is PILA PHARMA AB overvalued?
According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued.
Does PILA PHARMA AB pay dividends?
PILA PHARMA AB does not currently pay dividends.
What is PILA PHARMA AB’s EPS estimate?
PILA PHARMA AB’s EPS estimate is -0.04.
How many shares outstanding does PILA PHARMA AB have?
PILA PHARMA AB has 45,682,120 shares outstanding.
What happened to PILA PHARMA AB’s price movement after its last earnings report?
PILA PHARMA AB reported an EPS of -kr0.08 in its last earnings report, beating expectations of -kr0.22. Following the earnings report the stock price went down -6.769%.
Which hedge fund is a major shareholder of PILA PHARMA AB?
Currently, no hedge funds are holding shares in SE:PILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PILA PHARMA AB
Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.